Search
OPKO Health Inc
OPKAdd to Watchlist
1.540USD
+0.010+0.65%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.65%
5 Days
+3.36%
1 Month
+10.00%
6 Months
+22.22%
Year to Date
+22.22%
1 Year
+15.79%
Key Figures
1.530Open
1.570High
1.30MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.17%Turnover Ratio
1.530Prev. Close
1.525Low
1.38MTurnover
LossP/E Static
0.97P/B
0.00%Div Yield TTM
-10.69%ROA
1.60052wk High
0.58Volume Ratio
-53.22MNet Profit
755.09MShares
-0.2721EPS TTM
1.47Beta
-16.92%ROE
0.97752wk Low
2.94%Amplitude
21.57%Gross Margin
1.16BMarket Cap
4.14Reward/Risk
2.24%Risk Rate
TradingKey Stock Score of OPKO Health Inc
Currency: USD Updated: 2026-07-01Key Insights
OPKO Health Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 47 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.38.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
OPKO Health Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
OPKO Health Inc Highlights
StrengthsRisks
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 606.88M.
Fairly Valued
The company’s latest PE is -5.62, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 236.82M shares, decreasing 3.81% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 81.85K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
4.375
Target Price
+191.67%
Upside Space
OPKO Health Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
OPKO Health Inc Info
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Ticker SymbolOPK
CompanyOPKO Health Inc
CEOCruz (Tony F)
Website
Related Instruments
-0.47%
+2.14%
+3.75%
+4.88%
+1.94%
-1.15%
+4.36%
+4.28%
+5.65%
-0.07%
+1.59%
+6.00%
+1.33%
+2.31%
-2.91%
+2.48%
+2.63%
-0.52%
-0.58%
-0.95%Popular Instruments
52680.900
+426.600 (+0.82%)
29254.200
-545.100 (-1.83%)
7458.800
-16.700 (-0.22%)
14733.000
-622.000 (-4.05%)
67879.000
-1606.000 (-2.31%)
6339.000
+63.600 (+1.01%)
68.524
+0.556 (+0.82%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4124.760
+93.990 (+2.33%)
FAQs
What is the current price of OPKO Health Inc (OPK)?
The current price of OPKO Health Inc (OPK) is 1.53.
What is the symbol of OPKO Health Inc?
The ticker symbol of OPKO Health Inc is OPK.
What is the 52-week high of OPKO Health Inc?
The 52-week high of OPKO Health Inc is 1.60.
What is the 52-week low of OPKO Health Inc?
The 52-week low of OPKO Health Inc is 0.98.
What is the market capitalization of OPKO Health Inc?
The market capitalization of OPKO Health Inc is 1.16B.
Is OPKO Health Inc (OPK) currently rated as Buy, Hold, or Sell?
According to analysts, OPKO Health Inc (OPK) has an overall rating of Buy, with a price target of 4.38.
What is the Earnings Per Share (EPS TTM) of OPKO Health Inc (OPK)?
The Earnings Per Share (EPS TTM) of OPKO Health Inc (OPK) is -0.30.